Haematologica (Aug 2021)
Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma
- Johannes Duell,
- Kami J. Maddocks,
- Eva González-Barca,
- Wojciech Jurczak,
- Anna Marina Liberati,
- Sven de Vos,
- Zsolt Nagy,
- Aleš Obr,
- Gianluca Gaidano,
- Pau Abrisqueta,
- Nagesh Kalakonda,
- Marc André,
- Martin Dreyling,
- Tobias Menne,
- Olivier Tournilhac,
- Marinela Augustin,
- Andreas Rosenwald,
- Maren Dirnberger-Hertweck,
- Johannes Weirather,
- Sumeet Ambarkhane,
- Gilles Salles
Affiliations
- Johannes Duell
- Medizinische Klinik und Poliklinik II, Universitätsklinik Würzburg, Würzburg
- Kami J. Maddocks
- Department of Internal Medicine, Arthur G James Comprehensive Cancer Center, Ohio State University Wexner Medical Center, Columbus, OH
- Eva González-Barca
- Department of Hematology, Institut Catalá d’Oncologia (ICO), Hospital Duran i Reynals, Universitat de Barcelona, Barcelona
- Wojciech Jurczak
- Maria Sklodowska–Curie National Research Institute of Oncology, Kraków
- Anna Marina Liberati
- Università degli Studi di Perugia, Azienda Ospedaliera Santa Maria di Terni, Terni
- Sven de Vos
- Department of Medicine, Ronald Reagan UCLA Medical Center, Santa Monica, CA
- Zsolt Nagy
- 1st Department of Internal Medicine, Semmelweis University, Budapest
- Aleš Obr
- Department of Hemato-Oncology, Palacký University and University Hospital, Olomouc, Czech Republic
- Gianluca Gaidano
- Division of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara
- Pau Abrisqueta
- Department of Hematology, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron University Hospital, Barcelona
- Nagesh Kalakonda
- Molecular and Clinical Cancer Medicine, University of Liverpool and The Clatterbridge Cancer Centre, Liverpool
- Marc André
- Department of Haematology, Université Catholique de Louvain, CHU UCL Namur, Yvoir
- Martin Dreyling
- Department of Medicine III, LMU University Hospital, Munich
- Tobias Menne
- Department of Haematology, Freeman Hospital, Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle Upon Tyne
- Olivier Tournilhac
- Service d’Hématologie Clinique et de Thérapie Cellulaire, CHU Estaing, Clermont-Ferrand
- Marinela Augustin
- Department of Hematology and Oncology, Paracelcus Medical University, Klinikum Nürnberg, Nürnberg
- Andreas Rosenwald
- Institute of Pathology, University of Würzburg, Würzburg
- Maren Dirnberger-Hertweck
- MorphoSys AG, Planegg
- Johannes Weirather
- MorphoSys AG, Planegg
- Sumeet Ambarkhane
- MorphoSys AG, Planegg
- Gilles Salles
- Hématologie, Hospices Civils de Lyon and Université de Lyon, Lyon
- DOI
- https://doi.org/10.3324/haematol.2021.279802
- Journal volume & issue
-
Vol. 999,
no. 1
Abstract
Not available.
